Pharmaceuticals Australia

Australia mRNA Therapeutics Market Analysis, 2024–2034

Australia mRNA Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Application, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $213.1 Mn Estimated value
Estimate 2025 $228.8 Mn 1.4% of the global market
Projected 2034 $435.1 Mn 90.1% Adds $206.3 Mn over 9 forecast years
CAGR 2025–2034 7.4% Faster than 23% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Australia is 1.36% of the global market.
  • In APAC, the largest is China at $1.54 Bn.
  • Fastest growing: India at 8.6% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$206.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
mRNA Therapeutics Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $213.1 Mn — —
2025 (base) $228.8 Mn +$15.8 Mn —
2026 (forecast) $245.8 Mn +$16.9 Mn +7.4%
2027 (forecast) $264.0 Mn +$18.2 Mn +15.3%
2028 (forecast) $283.5 Mn +$19.5 Mn +23.9%
2029 (forecast) $304.5 Mn +$21.0 Mn +33.1%
2030 (forecast) $327.0 Mn +$22.5 Mn +42.9%
2031 (forecast) $351.2 Mn +$24.2 Mn +53.5%
2032 (forecast) $377.2 Mn +$26.0 Mn +64.8%
2033 (forecast) $405.1 Mn +$27.9 Mn +77%
2034 (forecast) $435.1 Mn +$30.0 Mn +90.1%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $16.85 Bn
  2. North America $8.69 Bn
  3. US $7.72 Bn
  4. Europe $3.50 Bn
  5. APAC $3.45 Bn
  6. China $1.54 Bn
  7. Canada $1.49 Bn
  8. Japan $901.0 Mn
  9. Latin America $814.7 Mn
  10. Middle East $791.1 Mn
  11. Germany $514.6 Mn
  12. UK $439.0 Mn
  13. Italy $420.1 Mn
  14. France $408.9 Mn
  15. Brazil $393.0 Mn
  16. Ecuador $375.1 Mn
  17. India $354.6 Mn
  18. Spain $309.6 Mn
  19. Mexico $285.9 Mn
  20. Saudi Arabia $287.2 Mn
  21. Africa $240.8 Mn
  22. Australia (this report) $228.8 Mn
  23. New Zealand $189.9 Mn
  24. Russia $177.9 Mn
  25. South Africa $119.1 Mn
  26. UAE $81.3 Mn
  27. Egypt $45.8 Mn
  28. Philippines $39.3 Mn
  29. Malaysia $31.2 Mn
  30. Hong Kong $29.8 Mn
  31. Thailand $22.6 Mn
  32. Singapore $21.8 Mn
  33. Kenya $13.5 Mn

The Australia mRNA Therapeutics Market Analysis Executive Summary

mRNA therapeutics use messenger RNA to make the body produce a protein, for vaccines, cancer treatments and rare diseases.

Key segments of the mRNA Therapeutics market include application (Infectious Disease Vaccines, Cancer Vaccines and Protein Replacement) and type (Prophylactic and Therapeutic).

Australia mRNA Therapeutics Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the mRNA Therapeutics market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the mRNA Therapeutics market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the mRNA Therapeutics market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for mRNA Therapeutics Market in Australia

The mRNA Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for mRNA Therapeutics Market in Australia

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for mRNA Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in mRNA Therapeutics right now, from free public sources.

Clinical trials

11 active trials in Australia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. ModernaTX, Inc. 15 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Sanofi 6 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Suzhou Abogen Biosciences Co., Ltd. 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Shenzhen Shenxin Biotechnology Co., Ltd 4 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Newish Biotech (Wuxi) Co., Ltd. 4 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 652 papers since 2021 (worldwide)

  1. Lipid nanoparticle-based mRNA delivery system for cancer management. Discover nano, 2026
  2. Cytokine networks in the tumor microenvironment: nanotherapeutic modulation of immune-cell communication and signaling networks. Nanomedicine (London, England), 2026
  3. Spray-Dried mRNA-LNP Powder Enabling Multi-Route Delivery With 3-Year Refrigerated Stability. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026
  4. PINPOINT enables non-destructive nanoscopic quality control of individual lipid nanoparticles and their mRNA cargo. bioRxiv : the preprint server for biology, 2026
  5. Augmenting the Cytotoxicity of Anticancer Peptide K6L9 by In Vitro-Synthesized mRNA. Applied sciences (Basel, Switzerland), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

mRNA Therapeutics in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on mRNA Therapeutics are running in Australia?
11 studies are recruiting, active or about to start in Australia.[4]
How much research is published on mRNA Therapeutics?
PubMed lists 652 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about mRNA Therapeutics in Australia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on vaccines and biologics and biosimilars

See the topic